Holen Sie sich die Stockscreener-App
1.70
4.29%
0.07
Handel nachbörslich:
1.68
-0.02
-1.18%
Essa Pharma Inc Aktie (EPIX) Neueste Nachrichten
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Scrip
Growth N. V. Biotech Sells 7,879,583 Shares of ESSA Pharma Inc. (NASDAQ:EPIX) Stock - MarketBeat
ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
ESSA Pharma shares downgraded after halting drug development By Investing.com - Investing.com Canada
ESSA Pharma terminates vital trial, leading Piper Sandler to cut shares rating - Investing.com Canada
ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials - Investing.com Canada
ESSA Pharma (NASDAQ:EPIX) Stock Rating Lowered by Oppenheimer - MarketBeat
2024-11-03 | Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to Connect | NDAQ:EPIX | Press Release - Stockhouse Publishing
Michael Jenson, PA-C, on Minnesota Urology’s Surgical Impotence Management Strategy program - Urology Times
ESSA Pharma tank as it drops Phase II masofaniten study - The Pharma Letter
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.69% - MSN
ESSA Pharma stock plunges to 52-week low of $1.55 By Investing.com - Investing.com South Africa
ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
United States shares higher at close of trade; Dow Jones Industrial Average up 0.69% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - Investing.com
Essa ends prostate cancer bid, seeks strategic options - BioWorld Online
ESSA Pharma tanks after terminating trial for its prostate cancer treatment - MSN
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results - Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results - Benzinga
ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC - OncLive
Dow Jumps 400 Points; US Adds 12,000 Jobs In October - Benzinga
Jones Trading cuts ESSA Pharma shares to hold from buy on trial data - Investing.com Australia
Essa Pharma Stock Crashes After Lead Drug Candidate Trial Flops: Retail Hopes Fade - Barchart
ESSA Pharma stock plunges to 52-week low of $1.55 - Investing.com
Why Is ESSA Pharma Stock Plunging On Friday?ESSA Pharma (NASDAQ:EPIX) - Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - Benzinga
Stock Market Movers Today • Top Gainers & Losers - Benzinga
ESSA Pharma tanks after terminating trial for its prostate cancer treatment (NASDAQ:EPIX) - Seeking Alpha
Jones Trading cuts ESSA Pharma shares to hold from buy on trial data By Investing.com - Investing.com South Africa
ESSA Pharma halts Phase II study of masofaniten in prostate cancer treatment - Yahoo Finance
Essa Pharma Shares Drop After Lead Drug Candidate Fails - MarketWatch
ESSA Pharma (NASDAQ:EPIX) Share Price Crosses Below Fifty Day Moving AverageShould You Sell? - MarketBeat
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - VictoriaNow
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer - StockTitan
When the Price of (EPIX) Talks, People Listen - Stock Traders Daily
ESSA Pharma Insiders Placed Bullish Bets Worth US$709.0k - Yahoo Finance
ESSA Pharma Insiders Added US$709.0k Of Stock To Their Holdings - Simply Wall St
ESSA Pharma (NASDAQ:EPIX) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
Centessa Pharmaceuticals (CNTA) - RTTNews
ESSA Pharma (NASDAQ:EPIX) Share Price Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
Metastatic Castration-Sensitive Prostate Cancer Clinical Trial Pipeline Insights Featuring 35+ Companies | DelveInsight - The Malaysian Reserve
Prostate Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 150+ Companies Working in the Domain - GlobeNewswire
Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Essa Pharma COO sells shares worth over $4,000 By Investing.com - Investing.com South Africa
Essa Pharma COO sells shares worth over $4,000 - Investing.com India
Innovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsight - GlobeNewswire
(EPIX) Technical Pivots with Risk Controls - Stock Traders Daily
ESSA Pharma (NASDAQ:EPIX) Stock Crosses Above Fifty Day Moving Average – Here’s What Happened - Defense World
ESSA Pharma (NASDAQ:EPIX) Stock Price Passes Above 50 Day Moving AverageTime to Sell? - MarketBeat
ESSA Pharma (NASDAQ:EPIX) Stock Price Passes Above 50-Day Moving Average of $5.52 - Defense World
ESSA Pharma (NASDAQ:EPIX) Stock Crosses Above 50 Day Moving Average of $5.52 - MarketBeat
(EPIX) Trading Signals - Stock Traders Daily
Global Prostate Cancer Diagnostics Market to Observe Stunning Growth at a CAGR of ~12% by 2030 | DelveInsight - The Malaysian Reserve
EPIX: Masofaniten Combination Therapy with Enzalutamide Increases rPFS; Increasing Valuation to $33 per Share… - Zacks Small Cap Research
ESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Above 50-Day Moving Average of $5.44 - Defense World
ESSA Pharma (NASDAQ:EPIX) Stock Passes Above Fifty Day Moving Average of $5.44 - MarketBeat
Apple, Tesla and ResMed Stir Afternoon Market Cap Stock Movers on Wednesday - Investing.com Australia
Apple, Tesla and ResMed Stir Afternoon Market Cap Stock Movers on Wednesday By Investing.com - Investing.com South Africa
ESSA Pharma maintains Overweight rating from Piper Sandler By Investing.com - Investing.com Canada
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):